Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2026-03-05 @ 7:57 AM
Study NCT ID:
NCT04957160
Status:
COMPLETED
Last Update Posted:
2024-12-17
First Post:
2021-01-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
Sponsor:
Ipsen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CLIN-60000-451
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None